
Valiant Organics (VALIANTORG) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
2.0B
Gross Profit
713.8M
35.02%
Operating Income
110.8M
5.44%
Net Income
42.0M
2.06%
Balance Sheet Metrics
Total Assets
11.8B
Total Liabilities
4.6B
Shareholders Equity
7.3B
Debt to Equity
0.63
Cash Flow Metrics
Revenue & Profitability Trend
Valiant Organics Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 7.2B | 7.2B | 10.5B | 11.5B | 7.5B |
Cost of Goods Sold | 4.6B | 5.0B | 7.0B | 7.8B | 4.2B |
Gross Profit | 2.6B | 2.3B | 3.5B | 3.7B | 3.4B |
Gross Margin % | 36.4% | 31.5% | 33.7% | 32.0% | 44.5% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | 212.2M | 271.9M | 243.0M | 197.3M |
Other Operating Expenses | 1.6B | 1.0B | 991.6M | 868.9M | 685.8M |
Total Operating Expenses | 1.6B | 1.2B | 1.3B | 1.1B | 883.1M |
Operating Income | 179.2M | 31.8M | 1.4B | 1.8B | 1.9B |
Operating Margin % | 2.5% | 0.4% | 13.1% | 15.5% | 24.8% |
Non-Operating Items | |||||
Interest Income | - | 1.6M | 3.9M | 8.5M | 4.8M |
Interest Expense | 236.4M | 163.4M | 107.9M | 64.8M | 50.0M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 21.5M | -86.9M | 1.4B | 1.8B | 1.8B |
Income Tax | 55.8M | -3.0M | 346.2M | 482.6M | 539.9M |
Effective Tax Rate % | 259.3% | 0.0% | 25.2% | 27.4% | 29.2% |
Net Income | -34.3M | -84.0M | 1.0B | 1.3B | 1.3B |
Net Margin % | -0.5% | -1.2% | 9.8% | 11.1% | 17.3% |
Key Metrics | |||||
EBITDA | 615.5M | 426.3M | 1.7B | 2.1B | 2.1B |
EPS (Basic) | - | ₹-3.07 | ₹32.45 | ₹41.72 | ₹44.68 |
EPS (Diluted) | - | ₹-3.07 | ₹31.50 | ₹40.50 | ₹40.97 |
Basic Shares Outstanding | - | 27292680 | 27153488 | 27153488 | 25643830 |
Diluted Shares Outstanding | - | 27292680 | 27153488 | 27153488 | 25643830 |
Income Statement Trend
Valiant Organics Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 71.0M | 34.8M | 77.5M | 250.5M | 128.3M |
Short-term Investments | 60.6M | 36.2M | 379.2M | 249.0M | 221.5M |
Accounts Receivable | 1.8B | 2.1B | 2.5B | 3.2B | 1.6B |
Inventory | 889.7M | 1.1B | 1.3B | 1.1B | 721.7M |
Other Current Assets | 157.3M | -1.0K | 7.2M | 232.6M | 1.0K |
Total Current Assets | 3.6B | 4.1B | 4.7B | 5.3B | 3.0B |
Non-Current Assets | |||||
Property, Plant & Equipment | 6.4B | 32.1M | 25.3M | 23.8M | 30.4M |
Goodwill | 251.1M | 248.9M | 248.7M | 246.6M | 246.7M |
Intangible Assets | 4.5M | 2.4M | 2.1M | 17.0K | 148.0K |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 50.9M | 55.8M | -39.9M | -1.0K | 1.0K |
Total Non-Current Assets | 8.3B | 8.4B | 7.7B | 6.7B | 5.7B |
Total Assets | 11.8B | 12.5B | 12.4B | 11.9B | 8.8B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 1.5B | 2.1B | 1.7B | 1.3B | 1.1B |
Short-term Debt | 2.0B | 1.8B | 2.0B | 2.6B | 1.3B |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 16.8M | 38.8M | 41.6M | 36.3M | 37.8M |
Total Current Liabilities | 3.7B | 4.1B | 3.9B | 4.1B | 2.7B |
Non-Current Liabilities | |||||
Long-term Debt | 508.2M | 744.8M | 716.9M | 1.1B | 753.0M |
Deferred Tax Liabilities | 343.9M | 291.6M | 332.4M | 266.1M | 203.0M |
Other Non-Current Liabilities | 1.0K | 4.0K | 2.0K | 1.0K | -1.0K |
Total Non-Current Liabilities | 888.3M | 1.1B | 1.1B | 1.3B | 971.2M |
Total Liabilities | 4.6B | 5.2B | 5.0B | 5.4B | 3.7B |
Equity | |||||
Common Stock | 280.0M | 275.8M | 271.5M | 271.5M | 271.5M |
Retained Earnings | - | 5.3B | 5.4B | 4.6B | 3.6B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 7.3B | 7.3B | 7.4B | 6.5B | 5.1B |
Key Metrics | |||||
Total Debt | 2.5B | 2.6B | 2.7B | 3.6B | 2.1B |
Working Capital | -127.7M | -4.4M | 783.4M | 1.2B | 326.3M |
Balance Sheet Composition
Valiant Organics Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 21.5M | -86.9M | 1.4B | 1.8B | 1.8B |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | 553.3M | 107.0M | 532.5M | -2.2B | -710.7M |
Operating Cash Flow | 832.9M | 196.0M | 2.0B | -368.5M | 1.2B |
Investing Activities | |||||
Capital Expenditures | -293.2M | -661.6M | -1.3B | -1.2B | -1.7B |
Acquisitions | - | - | - | - | 0 |
Investment Purchases | - | -10.1M | -329.6M | - | - |
Investment Sales | 63.7M | 3.5M | 0 | 0 | 253.4M |
Investing Cash Flow | -231.4M | -668.2M | -1.4B | -1.2B | -1.6B |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | -122.2M | - | -67.9M |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | - | - | - |
Financing Cash Flow | 154.9M | -191.5M | -672.3M | 1.1B | 398.2M |
Free Cash Flow | 256.0M | 90.7M | 862.2M | -1.5B | -562.5M |
Net Change in Cash | 756.4M | -663.8M | -95.5M | -518.9M | -9.8M |
Cash Flow Trend
Valiant Organics Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
28.47
Price to Book
1.40
Price to Sales
1.38
Profitability Ratios
Profit Margin
0.67%
Operating Margin
7.54%
Return on Equity
-0.52%
Return on Assets
-0.32%
Financial Health
Current Ratio
0.97
Debt to Equity
34.30
Beta
0.18
Per Share Data
EPS (TTM)
₹-1.25
Book Value per Share
₹262.55
Revenue per Share
₹248.48
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
valiantorg | 10.4B | 28.47 | 1.40 | -0.52% | 0.67% | 34.30 |
Navin Fluorine | 255.9B | 69.93 | 9.44 | 10.99% | 13.90% | 55.85 |
Deepak Nitrite | 253.2B | 41.67 | 4.70 | 11.85% | 7.58% | 23.36 |
India Glycols | 50.0B | 20.49 | 2.21 | 10.24% | 6.35% | 83.85 |
Styrenix Performance | 46.4B | 20.53 | 3.97 | 20.14% | 7.00% | 34.02 |
Gujarat Alkalies | 40.4B | 70.12 | 0.67 | -1.08% | -0.82% | 9.30 |
Financial data is updated regularly. All figures are in the company's reporting currency.